Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation

Blood

Volumn 117, Issue 3, 2011, Pages 764-771

  Moretta, Lorenzo ^a,b   Locatelli, Franco ^c   Pende, Daniela ^d   Marcenaro, Emanuela ^b   Mingari, Maria Cristina ^b,d   Moretta, Alessandro ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CHRONIC GRAFT VERSUS HOST DISEASE; DENDRITIC CELL; DONOR SELECTION; DRUG MEGADOSE; GENE FREQUENCY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HOST CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA REMISSION; LYMPH NODE; MEDIATOR; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 78751689960     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-264085     Document Type: Review

References (102)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
2. Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A. Human NK cells: origin, clonality, specificity and receptors. Adv Immunol. 1994;55:341-380. (Pubitemid 24175032)
3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
4. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004;23(2):255-259. (Pubitemid 38294490)
5. Parham P. The unsung heroes. Nature. 2003;423(6935):20.
6. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol. 2002;3(1):6-8. (Pubitemid 34065607)
7. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619-648. (Pubitemid 26130196)
8. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393.
9. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904. (Pubitemid 29241142)
10. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-251. (Pubitemid 34293425)
11. Lopez-Botet M, Llano M, Navarro F, Bellon T. NK cell recognition of non-classical HLA class I molecules. Semin Immunol. 2000;12(2):109-119. (Pubitemid 30199275)
12. Moretta A, Bottino C, Vitale M, et al. Activating receptors and co-receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223. (Pubitemid 32368034)
13. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-mediated cytolysis. Immunol Today. 2000;21(5):228-234. (Pubitemid 30259028)
14. Sivori S, Vitale M, Morelli L, et al. p46, a novel natural killer cell-specific surface molecule which mediates cell activation. J Exp Med. 1997;186(7):1129-1136. (Pubitemid 27441156)
15. Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998;188(5):953-960. (Pubitemid 28433421)
16. Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190(10):1505-1516.
17. Vitale M, Bottino C, Sivori S, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells is involved in non-MHC restricted tumor cell lysis. J Exp Med. 1998;187(12):2065-2072. (Pubitemid 28285576)
18. Cantoni C, Bottino C, Vitale M, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med. 1999;189(5):787-796. (Pubitemid 29189683)
19. Walzer T, Bléry M, Chaix J, et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A. 2007;104(9):3384-3389. (Pubitemid 46364168)
20. Vivier E, Spits H, Cupedo T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol. 2009;9(4):229-234.
21. Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206(7):1495-1503.
22. Wu J, Song Y, Bakker ABH, et al. An activating immunoreceptor complex formed by NKG2D and DAP 10. Science. 1999;285(5428):730-732. (Pubitemid 129505075)
23. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10):781-790.
24. Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev. 2001;181:158-169. (Pubitemid 32703404)
25. Moretta A, Bottino C, Tripodi G, et al. Novel surface molecules involved in human NK-cell activation and triggering of the lytic machinery. Int J Cancer. 1992;7(suppl):6-10.
26. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med. 1993;178(4):1397- 1406. (Pubitemid 23277371)
27. Sivori S, Parolini S, Falco M, et al. 2B4 functions as a co-receptor in human natural killer cell activation. Eur J Immunol. 2000;30(3):787-793. (Pubitemid 30216250)
28. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 1998;188(11):2083-2090. (Pubitemid 28562525)
29. Bottino C, Falco M, Parolini S, et al. NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative diseases. J Exp Med. 2001;194(3):235-246. (Pubitemid 32730798)
30. Falco M, Marcenaro E, Romeo E, et al. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. Eur J Immunol. 2004;34(6):1663-1672. (Pubitemid 39256048)
31. Vitale M, Falco M, Castriconi R, et al. Identification of NKp80, a novel triggering molecule expressed by human natural killer cells. Eur J Immunol. 2001;31(1):233-242. (Pubitemid 32096014)
32. Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol. 2006;12(12):1334-1342. (Pubitemid 46111255)
33. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573-581. (Pubitemid 26233311)
34. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003; 198(4):557-567. (Pubitemid 37040390)
35. Reymond N, Imbert A-M, Devilard E, et al. DNAM-1 and PVR regulate of monocyte migration through endothelial junctions. J Exp Med. 2004;199(10):1331-1341. (Pubitemid 38685725)
36. Sivori S, Falco M, Della Chiesa M, et al. CpG and dsRNA trigger human NK cells via TLR: induction of cytokine release and of cytolytic activity against tumors and immature DC. Proc Natl Acad Sci U S A. 2004;101(27):10116-10121. (Pubitemid 38891204)
37. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002;2(9):656-663.
38. Hanna J, Goldman-Whol D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006;12(9):1065-1074. (Pubitemid 44353388)
39. Vacca P, Cantoni C, Prato C, et al. Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction, between NK cells and trophoblast cells: evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol. 2008;20(11):1395-1405.
40. Vacca P, Cantoni C, Vitale M, et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci U S A. 2010; 107(26):11918-11923.
41. Bennet M. Biology and genetics of hybrid resistance. Adv Immunol. 1987;41:333-445.
42. Moretta A, Tambussi G, Bottino C, et al. A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells: role in cell activation and regulation of cytolytic function. J Exp Med. 1990;171(3):695-714. (Pubitemid 20088976)
43. Moretta A, Bottino C, Pende D, et al. Identification of four subset of human CD3-CD16+ NK cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med. 1990;172(6):1589-1598.
44. Moretta A, Vitale M, Bottino C, et al. p58 molecules as putative receptors for MHC class I molecules in human natural killer (NK) cells: anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med. 1993;178(2):597-604. (Pubitemid 23218208)
45. Wagtmann N, Biassoni R, Cantoni C, et al. Molecular clones of the p58 natural killer cell receptor reveal Ig-related molecules with diversity in both the extra- and intracellular domains. Immunity. 1995;2(5):439-449.
46. Colonna M, Samaridis J. Cloning of immunoglobulinsuperfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science. 1995;268(5209):405-408.
47. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med. 1994;180(2):537-544. (Pubitemid 24224130)
48. Pende D, Biassoni R, Cantoni C, et al. The natural killer cell receptor specific for HLA.A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140 kD disulphide-linked dimer. J Exp Med. 1996;184(2):505-518. (Pubitemid 26324104)
49. Döhring C, Scheidegger D, Samaridis J, Cella M, Colonna M. A human killer inhibitory receptor specific for HLA-A3. J Immunol. 1996;156(9):3098- 3101. (Pubitemid 26123520)
50. Sivori S, Falco M, Carlomagno S, et al. A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood. 2010;116(10):1637-1647.
51. Moretta A, Sivori S, Vitale M, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med. 1995;182(3):875-884.
52. Biassoni R, Cantoni C, Falco M, et al. The HLA-C specific "activatory" and "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med. 1996;183(2):645-650. (Pubitemid 26060796)
53. Bottino C, Sivori S, Vitale M, et al. A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. Eur J Immunol. 1996;26(8):1816-1824. (Pubitemid 26283156)
54. Stewart CA, Laugier-Anfossi F, Vély F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102(37):13224-13229. (Pubitemid 41325005)
55. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol. 2007;179(2):854-868.
56. Graef T, Moesta AK, Norman PJ, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med. 2009;206(11):2557-2572.
57. Mingari MC, Schiavetti F, Ponte M, et al. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int Immunol. 1995;7(4):697-703.
58. Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T cell activation and function. Hum Immunol. 2000;61(1):44-50. (Pubitemid 30058766)
59. Moretta L, Romagnani C, Pietra G, Moretta A, Mingari MC. NK-CTL, a novel HLA-E-restricted T cell subset. Trends Immunol. 2003;24(3):136-143. (Pubitemid 36263098)
60. Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol. 2004;4(3):190-198. (Pubitemid 38339085)
61. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
62. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood. 2003;101(9):3730-3740. (Pubitemid 36857966)
63. Ciccone E, Pende D, Viale O, et al. Involvement of HLA class I alleles in NK cell specific function: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J Exp Med. 1992;176(4):963-971.
64. Ciccone E, Pende D, Vitale M, et al. Self class I molecules protect normal cells from lysis mediated by autologous natural killer Cells. Eur J Immunol. 1994;24(4):1003-1006. (Pubitemid 24093802)
65. Costello RJ, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99(10):3661-3667. (Pubitemid 34534536)
66. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol. 2006;18(3):151-158. (Pubitemid 43817561)
67. Pende D, Spaggiari GM, Marcenaro S, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoid leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD122). Blood. 2005;105(5):2066-2073. (Pubitemid 40731793)
68. Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligandmismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009;113(13):3119-3129.
69. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulinlike receptors. Blood. 2010;115(6):1166-1174.
70. Copelan EA. Hematopoietic stem cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
71. Rocha V, Locatelli F. Searching for alternative donors of haematopoietic stem cell for paediatric patients. Bone Marrow Transplant. 2008;41(2):207-214. (Pubitemid 351188919)
72. Gluckman E. Cord blood transplantation. Biol Blood Marrow Transplant. 2006;12(8):808-812.
73. Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol. 2009;133(2):171-178.
74. Martelli MF, Aversa F, Bachar-Lustig E, et al. Transplants across human leukocyte antigen barriers. Semin Hematol. 2002;39(1):48-56. (Pubitemid 34081156)
75. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61(2):341-348. (Pubitemid 13137655)
76. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-1999. Lancet. 2003; 361(9357):553-560.
77. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995;1(12):1268-1273.
78. Reisner Y, Martelli F. Stem cell escalation enables HLA-disparate hematopoietic transplants in leukaemia patients. Immunol Today. 1999;20(8):343-347. (Pubitemid 29356426)
79. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948-3955. (Pubitemid 24362497)
80. Aversa F, Tabilio A, Velardi A, et al. Treatment of high risk acute leukaemia with T-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186-1193. (Pubitemid 28482127)
81. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-3454. (Pubitemid 46249699)
82. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574-3581.
83. Klingebiel T, Cornish J, Labopin M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplant in children with very-high risk acute lymphoblastic leukemia - impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010;115(17):3437-3446.
84. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397-4406. (Pubitemid 41775954)
85. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64-76. (Pubitemid 43830030)
86. Comoli P, Basso S, Zecca M, et al. Preemptive treatment of EBV-related post-transplant lymphoproliferative disorders after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7(6):1648-1655. (Pubitemid 46776261)
87. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562. (Pubitemid 20069191)
88. Moretta L, Locatelli F, Moretta A. Human NK cells: from HLA class I-specific Ig-like receptors to the therapy of acute leukemias. Immunol Rev. 2008;224:58-69.
89. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GVL effect. Blood. 2005;105(10):4135- 4142. (Pubitemid 40656166)
90. Vago L, Forno B, Sormani MP, et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood. 2008;112(8):3488-3499.
91. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644-650. (Pubitemid 38020523)
92. Falco M, Romeo E, Marcenaro S, et al. Combined genotypic and phenotypic killer cell Ig-like receptor analyses reveal KIR2DL3 alleles displaying unexpected monoclonal antibody reactivity: identification of the amino acid residues critical for staining. J Immunol. 2010;185(1):433-441.
93. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105(11):4416-4423. (Pubitemid 40720789)
94. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709-713. (Pubitemid 41117274)
95. Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class. Immunity. 2006;25(2):331-342. (Pubitemid 44224147)
96. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101(9):1835-1842. (Pubitemid 28226101)
97. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115(21):4293-4301.
98. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415. (Pubitemid 29343964)
99. Marcenaro E, Cantoni C, Pesce S, et al. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte- derived DC or EBV cell lines: regulation by KIR/HLA class I interaction. Blood. 2009;114(19):4108-4116.
100. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057. (Pubitemid 40504320)
101. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955-959.
102. Romagné F, André P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114(13):2667-2677.